Erbb2+metastatic breast cancer treatment after progression on trastuzumab: a cost-effectiveness analysis for a developing country

Objective Breast cancer (BC) and metastatic breast cancer (MBC) are significant causes of deaths amongst women worldwide, including developing countries. The cost of treatment in the latter is even more of an issue than in higher income countries. ErbB2 overexpression is a marker of poor prognosis a...